

30. (Amended) A [use according to any of claims 21-25 or a] method according to claim 26 [any of claims 26-29] wherein the MDC antagonist compound is selected from the group consisting of:

(a) a polypeptide fragment or analog of a vertebrate MDC that inhibits MDC activation of an MDC receptor;

(b) an antibody that specifically binds a vertebrate MDC polypeptide;

[(c) an MDC antagonist according to claim 20;]

[(d)] (c) a polypeptide capable of binding to a vertebrate MDC polypeptide and comprising an antigen-binding fragment of an anti-MDC antibody;

[(e)] (d) a polypeptide comprising the C-C chemokine receptor 4 (CCR4) amino acid sequence set forth in SEQ ID NO: 34 or comprising a continuous fragment thereof that is capable of binding to MDC; and

[(f)] (e) combinations of [(a)-(e)] (a)-(d).

31. (Amended) A [use according to any of claims 21-25 or a] method according to claim 26 [any of claims 26-29] wherein said MDC antagonist compound comprises an antibody substance that binds MDC, said antibody substance selected from the group consisting of monoclonal antibodies, polyclonal antibodies, single chain antibodies, chimeric, antibodies, and humanized antibodies.

New Abstract of the Disclosure:

Please amend the application by adding the attached Abstract of the Disclosure as page 118 of the application filed herewith, after the claims and prior to the drawing sheets.

Remarks

The claim amendments are made with reference to the current claim set, which is embodied in the annexes to the International Preliminary Examination Report.

The amendments to the claims are merely intended to minimize the filing fee and conform the claims to United States style, and are not intended to change the scope of the claims. The Applicant does not intend by these or any other amendments to abandon the subject matter of any claim as originally filed, and reserves the right to pursue such subject matter in this